Life sciences knowledge center

Life sciences knowledge center

Download on the App Store

Life sciences knowledge center episodes

  • Quenchbody Development

    Q-body is a new type of antibody-based probes that are highly innovative, versatile, and sensitive in detecting their corresponding antigens. It is constructed based on the principle of antigen-mediated fluorescent signal release. A Q-body is comprised of a fragment antibody (Fab or scFv) that is covalently modified by a fluorophore whose signal is, in the absence of the corresponding antigen, quenched by tryptophan (Trp) residues in the antibody. Upon antigen interaction, due to the change in antibody conformation, the Trp quenching effect is levitated, releasing the fluorescent signals. In principle, any antibody can be converted into a Q-body with proper protein engineering and conjugation strategies. The quenching effect is facilitated by adding of a small flexible linker that crosslinks the fluorophore to the Nt of the Fab or scFv antibody.

    12 min
  • ChimtoximAb Platform

    Currently, the conjugation strategies used to join payload and a guidance chimera are similar to those used in developing full-length Ab-based immuno-conjugates. To develop a ChimtoximAb, the designer often utilizes the exogenous effector moieties and antibody fragment molecules to create the conjugate. ChimtoximAb development is trending in terms of discovering the next-generation, functionally enhanced immuno-therapeutics with fragment antibodies as well as Fc-fusion proteins.

    11 min
  • ADC Development for Urothelial Tumor

    With seven approved antibody-drug conjugates (ADCs) and over 50 others in clinical development, significant advances have been made in recent years to bring ADC technology to the forefront of drug development.

    12 min
  • ADC Development for Osteosarcoma

    Osteosarcoma represents the most frequent malignant primary bone tumor, which mainly occurs in children and adolescents and causing high mortality. To date, despite significant advancements in the diagnosis and treatment of the cancer, long-term survival in both localized and metastatic osteosarcoma is still stagnated. Thus, conventional therapy is not fully adequate for osteosarcoma treatment and novel therapeutic approaches are required to improve outcomes.

    16 min
  • ADC Development for Prostate Cancer

    Prostate cancer is one of the most common cancers in men. The standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) have been assessed but failed to improve the overall survival (OS). Currently, novel treatment methods such as the targeted antibody-drug conjugates (ADCs) have been found to significantly improve the progression-free survival and OS rates.

    10 min
  • ADC Development for Pancreatic Cancers

    Pancreatic cancer represents one of the most lethal solid tumors, which is notoriously refractory to chemotherapy. Thus, the therapy outcome for patients with pancreatic cancer is still poor. A large number of new treatment approaches are being investigated actively, and antibody-drug conjugates (ADCs) showing unique advantages has been widely assessed in the treatment of pancreatic cancer.

    11 min
  • ADC Development for Multiple Myeloma
    Introduction of Multiple Myeloma

    MM is a relatively rare hematologic disorder characterized by proliferation of plasma cells, primarily involving the bone marrow. MM accounts for approximately 1% of all malignancies and approximately 10% of hematologic neoplasms. MM may present with elevated Calcium levels, renal insufficiency, anemia, and bone lesions as well as elevated levels of serum M protein or urine M protein or both. MM has 2 clinical variants: solitary bone plasmacytoma and extramedullary plasmacytoma. The diagnosis of MM is predominantly based on osteolytic bone destruction, plasma cell infiltration of bone marrow, hypercalcemia, anemia, and chronic renal insufficiency. A plain X-ray survey has been used to detect lytic bone lesions, to stage, and to monitor the disease in patients with MM for many years. CT is also indicated for early detection of bone lesions that may not be detected by conventional radiographic skeletal survey. Besides, different MRI protocols, radionuclide imaging, and PET imaging methods have been proposed in MM.

    11 min
  • Evaluation of Expression System

    The development of highly efficient expression system is important to the manufacture of vaccines. Vaccine production may require relatively small quantities of expressed material but represent a very diverse category of different target antigens with significant structural differences. Thus, vaccine production requires production systems with very large outputs, which drives the quest for efficient and cost-effective systems.

    9 min
  • Squalene

    Squalene is a squalene-based oil-in-water nano-emulsion with a formulation similar to MF59 that has been licensed in Europe for adjuvanted flu vaccines. Squalene is an oil more readily metabolized than the paraffin oil used in Freund's adjuvants. Squalene oil-in-water emulsion elicit both cellular (Th1) and humoral (Th2) immune responses.

    11 min
  • mRNA Vaccine

    The mRNA vaccine field, which represents a promising alternative to conventional vaccine approaches, is developing extremely rapidly because of their high potency, potential for rapid development and capacity for low-cost manufacture and safe administration

    12 min

About Life sciences knowledge center

From the publisher's feed

Life sciences knowledge center